Latest

14 stories

Hide weekly roundups

Yesterday

Regeneron registers prostate cancer bispecific trial; posts REGN5381 heart failure results

Weekly roundup, 4 itemsamrecibart cenvacibartUpdated

Regeneron grants long-term PSUs to co-founders, forms new subsidiary

An 8-K filed September 30, 2026 details a 10-year performance award for CEO Leonard Schleifer and CSO George Yancopoulos and discloses equity stakes in a newly formed subsidiary.

SEC filing

Tuesday, September 22

Regeneron registers two new trials: prion disease gene therapy and HS/obesity combo drug

Weekly roundup, 2 itemsALN-6457 olatorepatide

Friday, September 18

Regeneron's EYLEA HD posts Phase 3b safety results; dupilumab keloid study completes

Weekly roundup, 2 itemsaflibercept dupilumab

Wednesday, September 9

Regeneron registers two new cemiplimab trials in skin cancer and early lung cancer

Weekly roundup, 2 itemscemiplimab-rwlc Regeneron Pharmaceuticals

Monday, August 31

Sanofi's itepekimab COPD mechanism study AERIFY-3 posts results after 2025 completion

Trial updateitepekimab Regeneron Pharmaceuticals

Friday, August 21

Regeneron lists vonsetamig as available under compassionate use program

Trial updateRegeneron Pharmaceuticals vonsetamig

Wednesday, August 12

Regeneron registers Phase 1b trial of Factor XI/XII antibodies in dialysis patients

Trial updateamrecibart cenvacibart

Friday, August 7

Regeneron registers Phase 1 REGN17235 trial and joins Maryland-led lung cancer study

Weekly roundup, 2 itemscemiplimab-rwlc Regeneron Pharmaceuticals

Friday, July 31

FDA approves REMS-related supplement for Lynozyfic (linvoseltamab-gcpt)

Regulatory decisionlinvoseltamab-gcpt Regeneron Pharmaceuticals

Thursday, July 30

Quarterly updatecemdisiran fianlimab Regeneron Pharmaceuticals

Regeneron reports Q2 2026 results, cemdisiran filings accepted, fianlimab trial misses

Regeneron's second-quarter release recaps June 2026 FDA and EMA acceptance of cemdisiran filings for generalized myasthenia gravis and a Phase 3 fianlimab trial that missed its primary endpoint.

SEC filing

Monday, July 20

Regeneron backs two new trials: cemiplimab in transplant patients, blood cancer genetics study

Weekly roundup, 2 itemscemiplimab-rwlc Regeneron Pharmaceuticals

Friday, July 17

Regeneron registers Phase 3 PICC clot-prevention trial; Sanofi runs sarilumab study as collaborator

Weekly roundup, 3 itemsamrecibart cenvacibart

Wednesday, July 15

FDA approves subcutaneous Sarclisa Escena with on-body injector for multiple myeloma

Regulatory decisionisatuximab isatuximab-irfc